An Original Article published today reported a second-generation monoclonal antibody (mAb) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection.
The recently approved single-dose Beyfortus™ (nirsevimab) was found in a phase 3 clinical study that (0.3%) of infants who received Beyfortus were hospitalized for RSV-associated lower respiratory tract infection compared with 1.5% of those who received standard care.
Infants Protected From RSV Hospitalizations With Passive Immunization
Few Children With SARS-CoV-2 Develop Post-COVID-19 Condition
More children with positive SARS-CoV-2 tests have post-COVID-19 condition, but no significant difference seen in QoL for those with positive, negative tests
Post-COVID-19 Brain Health Impaired Versus Healthy Controls
However, brain health is comparable to that of patients hospitalized for other medical conditions of similar severity
Nearly Half of U.S. COVID-19 Cases Now Caused by JN.1 Variant
The speed at which the JN.1 variant has spread this month suggests it may spread more easily and be better at evading immune system